Endo Pharmaceuticals has agreed to pay North Carolina $1.5 million as part of a $172.9 multi-state settlement over allegations that the company unlawfully marketed one of its drugs, Attorney General Roy Cooper’s office announced Friday.
Endo has also agreed to pay a $20.8 million criminal fine to the federal government.
The company was accused of unlawfully marketing its drug Lidoderm to treat lower back pain and chronic pain between March 1999 and December 2007. The Food and Drug Administration had approved the drug only to treat pain associated with shingles.
Endo’s payment to North Carolina is related to the company’s marketing efforts resulting in false or fraudulent claims being submitted to state health programs, including Medicaid.
Digital Access for only $0.99
For the most comprehensive local coverage, subscribe today.
The $172.9 million settlement also includes 46 other states and the District of Columbia.
Endo is a subsidiary of Endo Health Solutions, a Pennsylvania-based pharmaceutical manufacturer.